The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|19|6|506-513

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.19, Iss.6, 2018-05, pp. : 506-513

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Olaparib, PARP1 inhibitor in ovarian cancer

By Marchetti Claudia   Imperiale Ludovica   Gasparri Maria Luisa   Palaia Innocenza   Pignata Sandro   Boni Terenzio   Bellati Filippo   Benedetti Panici Pierluigi  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 10, 2012-10 ,pp. : 1575-1584

Informa Healthcare

Access to resources Recommend Favorite

The Role of HE4 in Ovarian Cancer: Inhibiting Tumour Cell Proliferation and Metastasis

By Gao L   Cheng HY   Dong L   Ye X   Liu YN   Chang XH   Cheng YX   Chen J   Ma RQ   Cui H  

The Journal of International Medical Research, Vol. 39, Iss. 5, 2011-09 ,pp. : 1645-1660

Field House Publishing

Access to resources Recommend Favorite

P-selectin Cell Adhesion Molecule in Inflammation, Thrombosis, Cancer Growth and Metastasis

By  

Current Medicinal Chemistry, Vol. 11, Iss. 16, 2004-08 ,pp. : 2153-2160

Bentham Science Publishers

Access to resources Recommend Favorite

Strong growth predicted for ovarian cancer & IBS drug markets

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 602, 2010-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models

By  

Current Cancer Drug Targets, Vol. 16, Iss. 3, 2016-03 ,pp. : 226-237

Bentham Science Publishers

Access to resources Recommend Favorite